Copyright
©The Author(s) 2024.
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4194-4208
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4194
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4194
Figure 3 MiRNA-363-5p is sponged by steroid receptor RNA activator 1 in esophageal squamous cell carcinoma.
A: Steroid receptor RNA activator 1 (SRA1) was observed to be enriched in the cytoplasm of esophageal squamous cell carcinoma (ESCC) cells; B: Using lncRNABase, starBase, and RegRNA2.0, a total of 3 miRNAs were predicted to contain putative binding sites within SRA1; C: MiRNA-363-5p expression was inhibited in EC9706 and TE1 cells transfected with pcDNA3.1-SRA1; D: Upregulated miRNA-363-5p was found in ESCC tissues; E: MiRNA-363-5p is negatively correlated with SRA1; F and G: Luciferase activity of WT-SRA1 instead of MUT-SRA1 was evidently decreased by miRNA-363-5p upregulation in EC9706 and TE1 cells; H: RIP assay defined that both SRA1 and miRNA-363-5p could be remarkably enriched by anti-Ago2 in EC9706 and TE1 cells. aP < 0.01 vs negative control (NC); bP < 0.01 vs Adjacent; cP < 0.05 vs NC; dP < 0.01 vs IgG; NC: Negative control; LncRNA: Long non-coding RNA; SRA1: Steroid receptor RNA activator 1.
- Citation: He M, Qi Y, Zheng ZM, Sha M, Zhao X, Chen YR, Chen ZH, Qian RY, Yao J, Yang ZD. Long noncoding RNA steroid receptor RNA activator 1 inhibits proliferation and glycolysis of esophageal squamous cell carcinoma. World J Gastrointest Oncol 2024; 16(10): 4194-4208
- URL: https://www.wjgnet.com/1948-5204/full/v16/i10/4194.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v16.i10.4194